# Precigen

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Precigen
> Markdown URL: https://mediated.wiki/source/Precigen.md
> Source: https://en.wikipedia.org/wiki/Precigen
> Source revision: 1324335753
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

**Precigen, Inc.** (formerly **Intrexon Corporation**, [NASDAQ](/source/NASDAQ): PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Intrexon was founded in 1998, and is headquartered in [Germantown, Maryland](/source/Germantown,_Maryland).[2][3] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.[4]

## History

In 2015, Intrexon purchased [Oxitec](/source/Oxitec), a maker of genetically sterile insects, for $160 million.[5] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the [FDA](/source/FDA) for a [CAR-T](/source/Chimeric_antigen_receptor_T_cell) based therapy (investigational drug name PRGN-3006) to treat [acute myeloid leukemia](/source/Acute_myeloid_leukemia).[6][7] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.[8][9] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from [Randal J. Kirk](/source/Randal_J._Kirk).[7]

## See also

- [Ginkgo Bioworks](/source/Ginkgo_Bioworks)
- [Zymergen](/source/Zymergen)

## References

1. ["Precigen Revenue 2012-2021 | PGEN"](https://www.macrotrends.net/stocks/charts/PGEN/precigen/revenue)

1. ["Intrexon Corporation: Private Company Information"](https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=22365961). Bloomberg. Retrieved 2017-06-26.

1. ["Intrexon Corp (XON) Company Profile"](https://www.reuters.com/finance/stocks/companyProfile?symbol=XON). Reuters.com. Retrieved 2017-06-26.[dead link]

1. ["FAQ | Intrexon"](http://investors.dna.com/FAQ). *Intrexon InvestorRoom*. Retrieved 2018-03-28.

1. Nickel, Rod (15 September 2015). ["Market turbulence or not, North American investors plow into farm tech"](https://www.reuters.com/article/us-agriculture-tech-investment-idUSKCN0RF2FU20150915). *[Reuters](/source/Reuters)*. Retrieved 9 October 2015.

1. ["PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS"](https://clinicaltrials.gov/ct2/show/NCT03927261). [FDA](/source/FDA). Retrieved 6 April 2020.

1. Gilgore, Sara (6 January 2020). ["Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug."](https://www.bizjournals.com/washington/news/2020/01/06/intrexon-will-take-the-name-of-its-subsidiary-that.html). *[American City Business Journals](/source/American_City_Business_Journals)*. Retrieved 6 April 2020.

1. ["INTREXON CORPORATION IS NOW PRECIGEN, INC"](https://precigen.com/intrexon/). Precigen. Retrieved 6 April 2020.

1. Helmstetter, Michael (30 March 2020). ["The Promise And Fear Of Gene Editing"](https://www.forbes.com/sites/michaelhelmstetter/2020/03/30/the-promise-and-fear-of-gene-editing/#741a8c042b8e). *[Forbes](/source/Forbes)*. Retrieved 6 April 2020.

## External links

[Official website](https://precigen.com/)

---
Adapted from the Wikipedia article [Precigen](https://en.wikipedia.org/wiki/Precigen) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Precigen?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.